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Purpose: To analyze survival after early palliative radiotherapy (RT) in patients managed exclusively by regular
oncology staff or a multidisciplinary palliative care team (MPCT) in addition.
Methods: Retrospective matched pairs analysis. Comparison of two groups of 29 patients each: MPCT versus none.
Early RT started within three months after cancer diagnosis.
Results: Bone and brain metastases were common RT targets. No significant differences in baseline characteristics
were observed between both groups. Twelve patients in each group had non-small cell lung cancer. Median
performance status was 2 in each group. Twenty-seven patients in each group had distant metastases. Median
survival was not significantly different. In multivariate analysis, MPCT care was not associated with survival, while
performance status and liver metastases were. Rate of radiotherapy during the last month of life was comparable.
Only one patient in each group failed to complete radiotherapy.
Conclusions: MPCT care was not associated with survival in these two matched groups of patients. The impact
of MPCT care on other relevant endpoints such as symptom control, side effects and quality of life should be
investigated prospectively.
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Patients with advanced cancer often experience con-
siderable burden from symptoms such as pain, reduced
mobility, dyspnea, cough, bleeding or neurological def-
icits, which may improve after palliative radiotherapy
[1,2]. Given the complexity of symptoms and possibil-
ities for pharmacological and other interventions,
additional expertise from different health care profes-
sions might improve the overall benefit in terms of
symptom control, management of side effects and
quality of life (QoL). A recent retrospective analysis* Correspondence: carsten.nieder@nlsh.no
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unless otherwise stated.suggested that involving a multidisciplinary palliative
care team (MPCT) in addition to regular oncology staff
was associated with reduced likelihood of incomplete
palliative radiotherapy, although the observed differ-
ence was not statistically significant [3]. In multivariate
analysis, MPCT care was not associated with survival.
Most patients were treated late during the disease
trajectory.
In contrast, a randomized trial of early palliative care,
limited to patients with newly diagnosed metastatic
non-small cell lung cancer (NSCLC) and not tied to
radiotherapy utilization, showed marked differences
[4,5]. Participants (n = 151) were recruited at a single
institution during the time period between 2006 and
2009. Early palliative care integrated with standard on-
cology care was compared to standard oncology careThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sulted with a member of the MPCT within 3 weeks of
enrollment and at least monthly thereafter. Those
assigned to the standard care arm only met with the
MPCT on request from the patient, family, or oncolo-
gist. Early palliative care integrated with standard onco-
logic care led to significant improvements in QoL and
mood from baseline to 12 weeks. Fewer patients
received aggressive end-of-life care, yet median survival
was longer among patients receiving early palliative
care (11.6 versus 8.9 months).
Due to these observations and the heterogeneity of
the patient group included in our previous study, we
were interested in analyzing the impact of a MPCT on
survival after palliative radiotherapy, use of radiother-
apy near the end of life, and successful completion of
fractionated treatment in patients treated early after
diagnosis, arbitrarily defined as the first three months
from histological confirmation of the malignant dis-
ease. In order to further reduce bias, MPCT patients
were matched to standard care patients based on
established prognostic factors for survival, such as can-
cer type and performance status (PS). Compared to
our initial study, we extended the inclusion period
from 2009 to 2012.
Methods
We performed a retrospective analysis, using a database
in which all patients treated with palliative radiotherapy
at our hospital are registered. The patients started their
treatment in the time period from June 20, 2007 (date
of opening of the hospital’s radiotherapy facility) to
December 31, 2012. From the database we identified all
patients who received early palliative radiotherapy, i.e.
within three months from cancer diagnosis (n = 148).
The target volumes included distant metastases, lymph
node metastases or primary tumors. Due to their differ-
ent biological behavior, hematological malignancies and
primary central nervous system tumors were not in-
cluded. Stereotactic radiotherapy was not available.
Typical fractionation regimens were 3 Gy x10, 4 Gy x5
or 8 Gy x1. Then we used the hospital’s electronic
patient record (EPR) system to determine whether
standard oncology care or additional care by our
MPCT was provided. In many cases, the MPCT was
already involved before referral to radiotherapy, but we
also included patients with simultaneous start of radio-
therapy and MPCT care.
Referral to the MPCT was not standardized. Rather,
individual decisions were made by the treating clinical
oncologists responsible for chemo- and radiotherapy de-
livery, based on symptom severity, pain control or need
for initiation of home care services, taking into account
patient preferences. Our MPCT staff, which collaboratesclosely with primary health care facilities, family doctors
and home care providers in the region, includes several
professions: physician, nurse, psychologist, physiotherap-
ist, nutritionist, and priest. Regular weekly meetings be-
tween clinical oncologists and MPCT took place. Both
MPCT and radiotherapy facility operated every workday.
Time from referral to MPCT to first appointment was
1-2 days. All patients were covered by the national
public insurance system. Therefore, no out-of-pocket
costs were incured for any patient, regardless of man-
agement approach/treatment intensity. In other words,
no particular barriers prevented patients from access
to the MPCT.
Overall, 29 patients (20%) had received MPCT care in
addition to radiotherapy. Each patient was matched to
one patient managed with standard care not involving
the MPCT. The investigator that performed the match-
ing had access to baseline data, but was blinded to out-
comes. Identical Eastern Cooperative Oncology Group
(ECOG) PS and stage of disease (distant metastases or
no distant metastases) was required. Furthermore, age
(<10 years difference) and natural course of disease had
to be comparable (favorable biology vs. unfavorable biol-
ogy). The latter was based on a diagnosis of breast/pros-
tate cancer vs. lung cancer vs. other primary tumors. If
several matches were possible, systemic therapy was
added as selection parameter (ongoing systemic therapy
vs. none). If still more than one patient fulfilled these
criteria, the one treated in the closest temporal relation-
ship to the MPCT patient was chosen.
Radiation treatment details and date of death were
available from the EPR system. All patients had died by
the time of this analysis. Survival time was measured
from day 1 of radiotherapy. Actuarial survival curves
were generated by Kaplan-Meier method and compared
by log-rank test (IBM SPSS Statistics 21 (IBM Corpor-
ation, Armonk, NY, USA)). Prognostic factors achieving
statistical significance (defined as p < 0.05 throughout
this study in two-sided tests) were entered into multi-
variate survival analysis (Cox regression). Univariate
analyses of baseline parameters consisted of Pearson
chi-square and Fisher’s exact test.
We assessed the statistical fundament of this study,
assuming a mean survival time of 6 months (standard
deviation 4 months) in the non-MPCT group, as
reported previously [3]. With 29 patients per group,
the potential survival improvement in the MPCT
group would have to be 2.6 months (mean 8.6 ±
4 months) if one requires 80% statistical power and 5%
alpha error level.
The study was performed as a retrospective analysis of
early palliative radiotherapy. As a quality of care analysis,
no approval from the Regional Committee for Medical
and Health Research Ethics (REK) was necessary.
Table 1 Patient characteristics
Univariate analysis of baseline parameters for patients treated
with early palliative RT with or without care by multidisciplinary
palliative care team (MPCT)









3/4 10 10 1.0
Median age at RT
(years, range)
65 (51-82) 67 (42-81) 0.83
Gender
Male 14 15
Female 15 14 1.0
Primary tumor site
Prostate/Breast 1 1
Lung (small cell) 3 2
Lung (non-small cell) 12 12
Kidney 7 7
Others 6 7 0.83
Total no. of TV in RT course
1 19 19
2 7 8
3 3 2 0.88
Disease extent
Distant metastases 27 27
No distant metastases 2 2 1.0
Liver metastases
No 24 21
Yes 5 8 0.53
Lung metastases
No 17 21
Yes 12 8 0.41
Adrenal gland metastases
No 26 22
Yes 3 7 0.30
Brain metastases
No 20 20
Yes 9 9 1.0
Bone metastases
No 11 12
Yes 18 17 1.0
Metastatic spinal cord
compression
Table 1 Patient characteristics (Continued)
No 26 26
Yes 3 3 1.0
Steroids during RTa
No 10 7
Yes 19 22 0.36
Analgeticsa
No opioids 12 10
Opioids 17 19 0.79
Systemic cancer treatment
No 23 22




>2 11 9 0.23
Incomplete RTb
No 25 26
Yes 1 1 1.0
RT Radiotherapy, TV Target volume.
ainformation collected from patient charts rather than pharmacy databases.
bexcluding single fraction RT, which always was completed.
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The characteristics of the two groups are shown in
Table 1. Bone metastases (n = 11 in each group) and
brain metastases (n = 9 in each group) were common
radiotherapy targets. Regarding primary cancer type, the
largest subgroup was the one with NSCLC (n = 12 in
each group). Virtually all patients had distant metastases
(n = 27 in each group). Median ECOG PS was 2 in both
groups. Median age was 65 and 67 years, respectively.
No statistically significant differences in baseline charac-
teristics were found.
Failure to complete radiotherapy was similarly uncom-
mon in both groups (1 patient each). Median survival
was not significantly different, 94 days with MPCT and
155 days without MPCT, p = 0.35 (Figure 1). Two prog-
nostic factors were significantly associated with survival
in multivariate analysis: better ECOG PS (p = 0.001) and
absence of liver metastases (p = 0.04). Neither other
baseline characteristics nor MPCT care predicted sur-
vival in the Cox model. Rate of radiotherapy during the
last month of life was 28% in patients without MPCT
and 21% in patients with MPCT, p = 0.76).
Discussion
This study was designed as an expansion of our previous
work, which had demonstrated a numerically lower rate
of incomplete radiotherapy in patients managed by
MPCT in addition to regular staff [3]. Survival was not
Figure 1 Actuarial overall survival after early palliative radiotherapy (Kaplan-Meier estimate). Median 94 days in the group managed by
MPCT and 155 days in the group managed with standard care, p = 0.35.
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imbalances between the two groups, suggesting that
MPCT patients had more advanced disease, poorer PS
and larger symptom burden. In general, MPCT support
started quite late during the disease trajectory. Survival
of patients with metastatic breast, prostate or kidney
cancer is currently measured in years rather than
months [6-8]. A thought-provoking randomized study
suggested that early palliative care might be preferable
over standard oncology care [4,5]. The authors even re-
ported improved survival in their setting of NSCLC ther-
apy and consultation with the MPCT within 3 weeks of
enrollment. However, this was not the primary study
endpoint and might or might not have resulted from
imbalances in patient characteristics. All these findings,
especially the difference in survival, inspired us to
follow-up on our initial work and compare well-matched
groups of patients treated earlier during the course of
disease. Surprisingly, our choice of 3 months from
cancer diagnosis resulted in identification of a rather
small group of 29 patients. Narrowing this time interval
further, e.g. to 3-4 weeks, would render this analysis
meaningless, because group size and statistical power
would become unacceptable. Actually, early treatment
was not as early as anticipated, considering the fact that
more than 20% of the patients were found to have re-
ceived radiotherapy during the last month of life, i.e.
during terminal illness. Much lower rates were found in
previous analyses of patients who received radiotherapyat any point during the disease trajectory [9-12]. Our
data suggest that patients referred to palliative radiother-
apy soon after cancer diagnosis represent a prognostic-
ally unfavorable group.
It is noteworthy that few patients had PS 0-1 or
biologically favorable cancer types, while most had meta-
static disease. Use of steroids and opioid analgetics was
common. These findings underline that early radiother-
apy (most patients had not yet started systemic therapy
when radiotherapy commenced) is not synonymous to
limited disease extent or symptom burden. Obviously
there was a reason for referral to the MDCT early after
diagnosis in these 29 patients. As mentioned before,
MDCT care was not standard at our institution. Rather,
individual assessment was performed. This process is
relatively subjective, as emphasized by the fact that we
could match patients with comparable characteristics
who were not managed by our MDCT. The matching
aimed at elimination of important sources of bias. How-
ever, residual differences regarding prognostic factors
such as weight loss/cachexia, anemia and others still
might have influenced the results. Perfectly balanced
groups cannot be created from small databases. Further
drawbacks also exist: MPCT referral was not standard-
ized, patients from the no-MPCT group might have had
contact with the team at later time points after radio-
therapy was completed, statistical power was limited,
symptom severity and improvement were not assessed.
Clearly, our study cannot replace a sufficiently large
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include the amount of baseline information and com-
pleteness of follow-up.
As shown in the results section, we were not able to
demonstrate associations between MPCT care and over-
all survival or radiotherapy utilization near the end of
life. The MPCT group had numerically shorter median
survival, likely because only the sicker patients were re-
ferred. This might have caused imbalances in prognostic
factors, e.g. weight loss or dyspnea. Few patients were
unable to complete their prescribed course of radiother-
apy, probably because hypofractionated regimens
tailored to the expected prognosis were used. Other
advantages of MPCT care still might exist. As demon-
strated by Temel et al. these are measurable and clinic-
ally important [4]. It is also possible that survival
improvement only can be observed in prognostically fa-
vorable patients, such as those included in the NSCLC
trial [4], and that our patients who were in need of
radiotherapy, represented a negative selection. MPCTs
have been established in many hospitals with radiother-
apy facilities, and such teams often provide additional
supportive care interventions, physical exercise and ther-
apy, and spiritual care, focusing on patients and
caregivers [13-15]. Pituskin et al. reported on multidis-
ciplinary assessment of patients with symptomatic bone
metastases attending a dedicated outpatient palliative
radiotherapy clinic [16]. Consecutive patients were
screened for symptoms and needs relevant to their med-
ications, nutritional intake, activities of daily living, and
psychosocial and spiritual concerns from January 1 to
December 31, 2007. Consultations by appropriate team
members and resulting recommendations were collected
prospectively. Patients who received radiotherapy were
contacted by telephone four weeks later to assess symp-
tom outcomes. A total of 106 clinic visits by 82 individ-
ual patients occurred. In addition to pain relief,
significant improvements in tiredness, depression, anx-
iety, drowsiness and overall well-being were reported at
four weeks.
Conclusions
Increasing evidence suggests that MPCTs play an
important role in the multidisciplinary management of
patients with incurable cancer. Our data do not support
the hypothesis that this type of care also improves sur-
vival, at least in the context of palliative radiotherapy.
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